Masimo Launches Hemoglobin Hand-Held Tester Pronto-7

Masimo’s Prick-Free Pronto-7 for Painless Hemoglobin Spot Checking

IRVINE, Calif., January 26, 2012 — Masimo (NASDAQ: MASI) announced today that it will release fourth quarter and full year financial results for the period ended December 31, 2011, after the market closes on February 14, 2012. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.

A live webcast of the conference call will be available online from the investor relations page of the company’s corporate website at The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 42982286. After the live webcast, the call will be available on Masimo’s website through March 14, 2012. In addition, a telephonic replay of the call will be available through February 28, 2012. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 42982286.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care…by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at

No more needle pricks for patients getting their hemoglobin (Hgb) checked. Masimo has announced the limited worldwide release of its Pronto-7 hand-held device for spot-check testing of Hgb in

Masimo received EU’s CE Mark but has yet to obtain FDA approval.

Press release: Masimo Initiates Limited Market Release of Pronto-7™—New Revolutionary Palm-sized Device for Noninvasive Hemoglobin Spot-Check Testing at the Point-of-Care

Masimo received FDA 510(k) clearance for the Pronto-7 device that allows for quick and noninvasive bedside checking of total hemoglobin (SpHb), SpO2, pulse rate, and perfusion index. This is a unique tool that makes finger pricking and direct blood sampling unnecessary when watching patients’ hemoglobin levels, either in OR or in critical care settings.

The Pronto-7 already received the European CE mark back in 2010, but conducted a recall when the sensor was found to work poorly in low temperature. The issue was addressed and the device was reintroduced in August of last year.

With FDA 510(k) clearance and full commercial availability of the new Pronto-7 device, which includes expanded sensor size options to accommodate a wider range of finger sizes and the addition of a Max Sensitivity Mode, clinicians throughout the United States will be able to quickly and conveniently measure total hemoglobin, SpO2, pulse rate, and perfusion index— without removing a drop of blood.

With dimensions of just 13 cm x 7.2 cm x 2.5 cm (5.1? x 2.8? x 1?) and weight of 296 grams (10.5 ounces), the palm-sized Pronto-7 puts the power of noninvasive hemoglobin spot-check testing, along with SpO2, pulse rate, and perfusion index, into any clinician’s hands in various clinical settings, including physician offices, hospitals, and clinics. Because of the device’s embedded 802.11 b/g and Bluetooth communication capability, wireless printing or emailing of test results is enabled and future upgrades will allow for wireless transmission to electronic health record (EHR) systems.

Source :

Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 1822 posts on this blog.

Copyright © 2018 Medical Technology & Gadgets Blog All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes